Treatment Sequencing After Failure of the First Biologic in Cost-Effectiveness Models of Psoriasis: A Systematic Review of Published Models and Clinical Practice Guidelines

@inproceedings{Mauskopf2014TreatmentSA,
  title={Treatment Sequencing After Failure of the First Biologic in Cost-Effectiveness Models of Psoriasis: A Systematic Review of Published Models and Clinical Practice Guidelines},
  author={Josephine A. Mauskopf and M. T. Samuel and D McBride and Usha G. Mallya and Steven R. Feldman},
  booktitle={PharmacoEconomics},
  year={2014}
}
To analyse the treatment sequencing assumptions after failure on a first-line biologic in cost-effectiveness models of treatment of moderate to severe plaque psoriasis, and to compare them with the most recent treatment guidelines. A systematic search of MEDLINE, Embase, EconLit and the Cochrane Library databases used free text and Medical Subject Headings terms including psoriasis, biologic therapies indicated for psoriasis, and all types of economic evaluations. Two researchers performed 2… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 41 references

Effect of treatment switch on the cost-effectiveness of biologics in psoriasis in Peru and Colombia

JC Alandete
Value Health • 2011
View 11 Excerpts
Highly Influenced

German S3-guidelines on the treatment of psoriasis vulgaris (short version)

Archives of Dermatological Research • 2012
View 9 Excerpts
Highly Influenced

European S3-guidelines on the systemic treatment of psoriasis vulgaris.

Journal of the European Academy of Dermatology and Venereology : JEADV • 2009
View 4 Excerpts
Highly Influenced

Etanercept and efalizumab for the treatment of psoriasis: a systematic review.

Health technology assessment • 2006
View 11 Excerpts
Highly Influenced

Economic analysis of etanercept as continuous or paused therapy in moderate to severe psoriasis from a private perspective in Brazil

RA Fernandes, MLS Takemoto, LM Amaral
Value Health • 2012
View 5 Excerpts
Highly Influenced

Economic analysis of etanercept as continuous or paused therapy in moderate to severe psoriasis from a public perspective in Argentina

RA Fernandes, MLS Takemoto, LM Amaral
Value Health • 2012
View 5 Excerpts
Highly Influenced

Economic analysis of etanercept as continuous or paused therapy in moderate to severe psoriasis from a public perspective in Brazil

RA Fernandes, MLS Takemoto, LM Amaral
Value Health • 2012
View 5 Excerpts
Highly Influenced

Economic analysis of etanercept as continuous or paused therapy in moderate to severe psoriasis from a public perspective in Venezuela

RA Fernandes, MLS Takemoto, LM Amaral
Value Health • 2012
View 5 Excerpts
Highly Influenced

Economic analysis of etanercept as continuous or paused therapy in therapy in moderate to severe psoriasis from a public perspective in Colombia

RA Fernandes, MLS Takemoto, LM Amaral
Value Health • 2012
View 5 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…